If prostate cancer progresses to metastatic castration-resistant prostate cancer (mCRPC), this is then treated with antagonists of gonadotropin-releasing hormone and androgen receptor (AR), which, altogether, lower testosterone activities; abiraterone can be included in the treatment to further inhibit androgen synthesis [34,35,36]. Here, AR is linked to Familial prostate cancer.